Clinical Characteristics Analysis and Prediction Model Establishment of Fatal Esophageal and Gastric Variceal Bleeding
NCT ID: NCT05613309
Last Updated: 2023-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
3000 participants
OBSERVATIONAL
2022-12-01
2023-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Risk Prediction of Bleeding in Liver Cirrhosis by Combi-elastography
NCT04640350
Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study
NCT02593799
Development and Validation of an Noninvasive Model for Predicting High Risk Esophageal Varices in Cirrhosis
NCT04210297
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
NCT05629845
Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular Carcinoma
NCT05017922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with acute varicose hemorrhage in Renmin Hospital of Wuhan University in recent 10 years
In this study, patients with liver cirrhosis and acute variceal bleeding in Renmin Hospital of Wuhan University in the past 10 years will be selected as the research objects. Patients will be divided into survival and death groups according to whether they died 6 hours after admission. The differences in clinical data between the two groups will be compared and analyzed to decide the risk factors for early death and establish a mortality risk prediction model.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. AVB was confirmed by endoscopy without special medical history;
Exclusion Criteria
2. Patients with upper gastrointestinal bleeding have no evidence of AVB.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Renmin Hospital of Wuhan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ChenMingkai
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mingkai Chen, PHD
Role: STUDY_DIRECTOR
Renmin Hospital of Wuhan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mingkai Chen
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WDRY2022-K204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.